Last reviewed · How we verify
NCT06124313
A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health
NA trial testing Vaginal Probiotic in Irritable Bowel Syndrome in 40 participants. Completed in 14 January 2024.
14 January 2024
Quick facts
| Lead sponsor | Rael |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 14 September 2023 |
| Primary completion | 14 January 2024 |
| Estimated completion | 14 January 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Vaginal Probiotic — full drug profile →
Conditions studied
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
- Vaginal Health — all drugs for Vaginal Health →
Sponsor
Rael — full company profile →
Who can join
Adults 18 to 40, female only, with Irritable Bowel Syndrome or Vaginal Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06124313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Irritable Bowel Syndrome
Currently open trials in the same condition.
- NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
- NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting
Other Rael trials
Trials by the same sponsor.
- NCT06939972 — A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle · NA · completed
- NCT06120452 — A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation · NA · completed
- NCT06124326 — A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome · NA · completed
- NCT06124300 — Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06124313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rael
- Last refreshed: 23 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing